Delta4 | AI Drug Discovery & Indication Expansion

Leveraging AI to discover new indications for drugs with known safety profiles.

Iguratimod Case Study:

Identifying The Treatments of Tomorrow, Today!

Delta4, a frontrunner in the TechBio realm, unveiled potential new indications for the drug Iguratimod using its AI-powered in-silico platform, Hyper-C. Tapping into sophisticated algorithms, Hyper-C meticulously analyzed the Iguratimod drug model against an extensive catalog of disease profiles, pinpointing potential avenues for indication expansion. This data potentially revolutionizes how we perceive and utilize Iguratimod in the medical field.

Dive into our video presentation to uncover the intricate processes by which Hyper-C made these revelations and explore the promising new indications. Don’t miss out on this exciting journey into the future of drug indication expansion!

Iguratimod Case Study
A wire mesh sphere on a black background.

What We Do

Delta4 is an AI drug discovery TechBio company.

We focus on discovering undetected relationships between drugs with a known safety profile and diseases to identify new indications. We do this by utilizing Hyper-C, our artificial intelligence powered platform that allows us to detect these relationships with unprecedented speed.

Hyper-C is operated by our team of highly skilled computational biologists who carefully analyze the data to produce unique insights and detect drug indication expansion opportunities.

The results are new therapy options that find their way to patients faster, more cost-effectively, and more efficiently than ever before.

Hyper-C | Our Platform

Intelligent systems for unparalleled results.

Hyper-C stands for Hyper Connectivity. It’s our proprietary AI platform housing an enormous collection of algorithmic intelligence.

The platform feeds on big data and uses its algorithms and data integration to build molecular models which go through an iterative refinement process matching them to diseases. This sophisticated process utilizing thousands of pre-computed models effectively matches compounds to diseases for more efficient biological testing and clinical trials.

Hyper-C is unique in that unlike other AI platforms, it eliminates the black box problem. Its results provide a clear mechanism of action hypothesis that aids in regulatory requirements.

In-silico AI platform
De-risking with existing safety profiles
70 man-years of development
In-silico AI platform
De-risking with existing safety profiles
70 man-years of development
Learn more about our platform, the exceptional team that operates it, and how it can help you identify new indications for compounds with a higher probability of success in the biological testing and clinical phases.

Our Process

An efficient and cost-effective methodology streamlined for success

While Hyper-C's AI makes it one of the most formidable tools on the market for repurposing drugs with known safety profiles, it's still only a tool.
Delta4's success lies in its powerful 7-step drug discovery process to efficiently and cost-effectively develop assets.
Our approach combines the best of state-of-the-art artificial intelligence in drug discovery with the invaluable skills of our talented computational biologists.
The process begins by harvesting high-quality data on potential drug candidates, chemical structures, and human diseases that Hyper-C integrates through an iterative process to build molecular models.
Once Hyper-C generates a shortlist of proposed matches, our team reviews the data to identify the best candidates to move on to the biological testing (in-vitro/in-vivo) phase and then clinical testing.
Our drug development process reliably gets drugs to market faster and more reliably than ever before.
Previous slide
Next slide
Learn more about our process and our pipeline of assets to see what we’re working on.

Who We Are

Crafting the treatments of the future.

Delta4 is a TechBio company focused on expanding indications for existing drugs with known safety profiles.

We accelerate new treatment options to improve the health of patients and get them into their hands faster, more safely, and more efficiently than the traditional approach.

scientist at the computer

Our Partners & Clients

It’s an honor and a privilege to be working with the best of the best!

Proud Member of

Streamlining Transparency and Cooperation provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.

Latest News & Events

Stay up to date with all our activities

From the latest news and press releases to blog posts and important industry events, check here to stay current with what we’re up to and what we’re watching.
Hands holding a paper cutout of a red kidney on a light blue background.

The Path to New Therapies for Focal Segmental Glomerulosclerosis (FSGS)

Developing new treatments for complex diseases presents a myriad of challenges, ranging from understanding the disease’s mechanisms to ensuring the ...
Read More
A doctor holding up a tablet with an image of a kidney.

Pioneering the Future of Nephrotic Syndrome Research with ARREST-NEPHROSIS

Nephrotic Syndrome affects millions globally, presenting a significant health burden with its hallmark symptoms of severe proteinuria and edema. The ...
Read More
group of attendees at Bio-Europe Spring

Delta4 At BIO-Europe

Delta4 at BIO-Europe 2023: Fostering Partnerships and Driving Innovation We are excited to share Delta4’s presence at the recently concluded ...
Read More

Get Involved

Learn how you can contribute to the exciting work happening at Delta4


Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.


Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.